Home›Clinical trials›Glutide for Ending Methamphetamine

A study of a GLP-1 medicine, semaglutide, in people with methamphetamine dependence.

Recruiting now. Registry record last updated June 3, 2026.

Who can join
Adults 18 to 65, have methamphetamine dependence, BMI 25+.
What you take
Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 4 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor San Francisco Department of Public HealthDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 162

What this study is for

Primary condition: Methamphetamine-dependence.

Full scientific study title: Glutide for Ending Methamphetamine.

Who can join

Age18 to 65SexAnyBMI25 or higher

Adults 18 to 65, have methamphetamine dependence, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Ability to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study,
  • Age 18 - 65 years inclusive,
  • Moderate to severe Methamphetamine Use Disorder by Structured Clinical Interview for DSM Disorders (SCID),
  • Self-reported methamphetamine use ≥15 days out of the past 30,
  • Methamphetamine-positive urine during screening and run-in period,

Key exclusion criteria

  • Uncontrolled hypertension or systolic BP \>160 mmHg and/or diastolic BP \>90 mmHg, averaged from three measurements,
  • Diabetes (type 1 or 2), hemoglobin A1c ≥ 6.5 at screening, or history of diabetic ketoacidosis,
  • History or current hypoglycemia (blood glucose \<70 mg/dL),
  • History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
  • History of heart failure or severe gastrointestinal disease (including acute or chronic pancreatitis, any gastric emptying disorder, gallbladder disease; any gastric resection),

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

California1 site

Timeline

Started enrolling: February 26, 2026. Expected completion: February 15, 2030. Last updated on ClinicalTrials.gov: June 3, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.